# Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy

> **NCT00095836** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 27 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00095836
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-05-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095836, "Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00095836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*